JPRN-UMIN000016608
Completed
N/A
Clinical Research on the efficacy evaluation and the biomarker of nivolumab to an advance malignant melanoma - CREATIVE (CSPOR-melanoma)
Conditionsmalignant melanoma
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- malignant melanoma
- Sponsor
- Public Health Research Foundation
- Enrollment
- 128
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)Patients with comorbid active infection 2\)Patients with interstitial lung disease or pulmonary fibrosis 3\)Patients who are or may be pregnant 4\)Patients who are difficult to treat due to psychosis or psychiatric symptoms 5\)Patients judged to be ineligible for the study by an attending physician
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not Yet Recruiting
Phase 1
Clinical Efficacy Evaluation and Mechanism Study of Anti-Hepatic Fibrosis Effectively Treated Prescription by Supplementing Deficiency and Clearing CollateralsITMCTR2100005161Chengdu University of Traditional Chinese Medicine
Not Yet Recruiting
Phase 1
Study for clinical efficacy evaluation and mechanism of Chinese medicine in relieving antibiotic resistance and sensitizing resistant bacteria by taking drug-resistant bacterial diarrhea as an exampleDrug-resistant bacterial diarrhea in childrenITMCTR1900002803Affiliated Hospital of Changchun University of Traditional Chinese Medicine
Unknown
Phase 2
A clinical trial to study the effect of Unani drug in the treatment of liver cirrhosis.CTRI/2021/09/036474Deptt of Moalajat School of Unani Medical Education and Research Jamia Hamdard University
Completed
N/A
Study on evaluation of therapeutic efficacy and search for a therapeutic biomarker in dry eye with rebamipide eye drop treatment.Dry eyeJPRN-UMIN000009371Division of Ophthalmology, Department of Visual Sciences, Nihon University School of Medicine.55
Not Yet Recruiting
N/A
A study to assess the clinical effectiveness and safety of intravesical mitomycin-C and gemcitabine sequential therapy in patients with high risk non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG) Therapy: Prospective, multicenter, open-label trialKCT0009491ational Cancer Center82